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Background: Omega-3 fatty acids confer beneficial health effects, but North Americans are lacking in their dietary
omega-3-rich intake. Supplementation is an alternative to consumption of fish; however, not all omega-3 products
are created equal. The trial objective was to compare the increases in blood levels of omega-3 fatty acids after
consumption of four different omega-3 supplements, and to assess potential changes in cardiovascular disease risk
following supplementation.
Methods: This was an open-label, randomized, cross-over study involving thirty-five healthy subjects. Supplements
and daily doses (as recommended on product labels) were:
Concentrated Triglyceride (rTG) fish oil: EPA of 650 mg, DHA of 450 mg
Ethyl Ester (EE) fish oil: EPA of 756 mg, DHA of 228 mg
Phospholipid (PL) krill oil: EPA of 150 mg, DHA of 90 mg
Triglyceride (TG) salmon oil: EPA of 180 mg, DHA of 220 mg.
Subjects were randomly assigned to consume one of four products, in random order, for a 28-day period, followed
by a 4-week washout period. Subsequent testing of the remaining three products, followed by 4-week washout
periods, continued until each subject had consumed each of the products. Blood samples before and after
supplementation were quantified for fatty acid analysis using gas chromatography, and statistically analysed using
ANOVA for repeated measures.
Results: At the prescribed dosage, the statistical ranking of the four products in terms of increase in whole blood
omega-3 fatty acid levels was concentrated rTG fish oil > EE fish oil > triglyceride TG salmon oil > PL krill oil. Whole
blood EPA percentage increase in subjects consuming concentrated rTG fish oil was more than four times that of
krill and salmon oil. Risk reduction in several elements of cardiovascular disease was achieved to a greater extent by
the concentrated rTG fish oil than by any other supplement. Krill oil and (unconcentrated) triglyceride oil were
relatively unsuccessful in this aspect of the study.
Conclusion: For the general population, the form and dose of omega-3 supplements may be immaterial.
However, given these results, the form and dose may be important for those interested in reducing their risk of
cardiovascular disease.
Trial registration: ClinicalTrials.gov: NCT01960660.
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The health benefits of omega-3 fatty acids (ω-3 FAs)
have been extensively examined in many published stud-
ies, and these benefits have been observed in patients
with a diversity of conditions and diseases, including car-
diovascular disease (e.g. atrial fibrillation, atherosclerosis,
thrombosis, inflammation, sudden cardiac death, etc.),
age-related cognitive decline, periodontal disease, rheuma-
toid arthritis, etc. [1-9]. Although the consumption of fatty
fish is the recommended mode of incorporation of ω-3
FAs into the North American diet, fish consumption in
North America is much lower than in parts of European
and Asian countries [10-19].
Supplementation with ω-3 FAs may provide a viable
alternative to fish consumption. In a recent U.S. survey,
sixty-eight percent of adults take some form of supple-
mentation, and of those, nineteen percent consume ω-3
supplements [20]. Not all ω-3 supplements are created
equal, however, and there is conflicting information in
the scientific literature with regard to the relative bio-
availability of different ω-3 supplements. The most im-
portant ω-3 FAs, eicosapentaenioc acid (EPA) and
docosahexaenoic acid (DHA) may be present in an ethyl
ester (EE) form, in a triglyceride (TG) form, as Free Fatty
Acid (FFA) or as phospholipids (PL). It has been sug-
gested that the form in which the ω-3FA is consumed
may affect its relative bioavailability. For example, if the
ω-3FA is in the sn-2 position on the TG glycerol back-
bone, then after cleavage of the long-chain fatty acids
(LCFAs) on the sn-1 and sn-3 positions, the sn-2 FA, still
attached to the glycerol backbone, is preferentially
absorbed as a monoglyceride by passive diffusion, while
the cleaved LCFAs require a protein mediator for ab-
sorption. Additionally, the distribution of these long-
chain fatty acids (LCFAs) between the inner and outer
positions of intestinally-resynthesized TGs may influence
their incorporation into plasma lipoprotein fractions
[21].
The superior bioavailability of TG versus EE forms of
ω-3FA was first identified by several researchers more
than thirty years ago [22-24]. This finding has been con-
firmed more recently, although there have been some
contrary findings [25-29]. Research on the relative bio-
availability of PL forms of ω-3FA is limited and incon-
clusive. In the most recent publication on this issue, krill
oil, the most common phospholipid supplement, was
not significantly different than re-esterified TG or EE in
bioavailability of DHA or EPA +DHA, although there
was a trend towards an increased bioavailability of EPA
with krill oil [30]. However, the krill oil used in this
study contained significant amounts of both PL and
FFAs, and the latter has been shown to exhibit slightly
superior bioavailability of ω-3FA, compared to the EE
form [31].Omega-3 supplement manufacturers appear to be mak-
ing use of published bioavailability literature when they
recommend suitable dosages on the labels of their prod-
ucts. Thus, there is a wide range of recommended dosages
available, such that the consumer may not be achieving an
intake or blood level of ω-3 FAs that is conducive to pos-
sible health improvements and/or disease risk reduction.
The objective of this study was to compare the increases
in blood levels of omega-3 fatty acids after consumption
of four different omega-3 supplements, and to assess po-
tential changes in cardiovascular disease (CVD)risk fol-
lowing supplementation.
The daily dose of each supplement, as recommended
on the label by the manufacturer, was as follows:
Concentrated Triglyceride (rTG) fish oil: EPA of
650 mg, DHA of 450 mg
Ethyl Ester (EE) fish oil: EPA of 756 mg, DHA of
228 mg
Phospholipid (PL) krill oil: EPA of 150 mg, DHA of
90 mg
Triglyceride (TG) salmon oil: EPA of 180 mg, DHA of
220 mg.
All samples had tocopherols added for antioxidant
function, although none listed the quantity on product
labels. The PL and TG supplements also contained the
naturally-occurring antioxidant astaxanthin, at 1.5 mg
and 2.5 μg respectively. Each supplement was analysed
for omega-3 fatty acid content at the beginning and end
of the trial. Levels of omega-3 fatty acids were un-
changed, and matched target values.
Results
A total of 46 prospective participants were pre-screened,
of whom 35 were found to be eligible. They were en-
rolled, randomized and received at least one dose of
study supplement. Three participants prematurely dis-
continued, two of whom experienced minor adverse
events and one whose time became limited. Data from
32 participants was available for analysis.
Subject characteristics
Baseline subject characteristics are presented in Table 1.
There were no significant changes in any of these pa-
rameters during the trial, nor were there any serious ad-
verse events. Mean compliance rate was 99%, and no
participant consumed less than 80% of their study
medication.
Fatty acid results
In statistical testing for effect of order of treatment,
there were no significant difference among the four or-
ders of treatment, and baseline levels of all biomarkers
Table 1 Baseline characteristics of trial participants, by
gender





1.726 77.08 120.7 78.8 25.81





1.764 80.89 126.2 77.9 26.04





1.685 73.04 114.9 79.7 25.57
SD 13 0.093 26.42 10.6 8.3 8.08
1HT: Height (m); 2WT: Weight (kg): 3BPS: Systolic blood pressure; 4BPD:
Diastolic Blood.
Pressure; 5SD: Standard Deviation.
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other when comparing the four groups (data not
shown).
Abbreviations used in the following tables, and not yet
defined, are as follows:
AA: Arachidonic Acid; DPA: Docosapentaenoic Acid; ω-
3 FA: omega-3 fatty acids; ω-6-FA: omega-6 fatty acids;
ω3:ω6: omega-3:omega-6 Ratio; ω-6: ω:3: omega-6:omega-
3 Ratio; CP: Comparator product; SD: Standard Deviation.
Fatty acids and calculated fatty acid combination re-
sults are presented in Table 2.
Figure 1 illustrates the EPA +DHA changes during the
supplementation period, for the four comparator products.
The changes and percentage changes between Day 0
and Day 28 for the fatty acids of interest, as well as the
statistical significance, are shown in Table 3.
From Table 3, it is noted that the increase in omega-3
fatty acids after rTG supplementation is statistically
greater than for the other products. Also, the AA:EPA
ratio is statistically lower after rTG supplementation
than for the other products.
Figure 2 illustrates the EPA, DHA and EPA +DHA
percentage changes and the results of statistical compar-
isons of those changes, among the comparator products.
As with Figure 1, Figure 2 demonstrates that rTG sup-
plementation produced a significant improvement over
the other three products in both DHA increase and EPA +
DHA increase, from Day 0 to Day 28. Supplementation
with this product also produced a statistically higher
increase in whole blood EPA than the PL and TG
products. From Tables 2 and 3, and Figures 1 and 2, it
appears that the order of efficacy in raising the blood
levels of the ω-3FA of interest (primarily EPA and DHA)
is as follows: rTG > EE > TG > PL, based on the percentage
changes and relative p-values for the various ω-3FAs and
FA combination and ratio increases, as well as the statis-
tical comparisons among the four comparator products.
These results are to be expected, given the relative daily
doses of EPA and DHA in each of the supplements. These
were the daily doses recommended by the manufacturers,
as listed on each label for the four supplements.Comparisons are more appropriate for supplements
with similar intakes of specific fatty acids. For example,
the rTG and EE groups had somewhat similar daily in-
takes of EPA, 650 mg and 756 mg, respectively. In
Table 3, it is noted that the mean percentage increase in
whole blood EPA for the rTG and EE groups was very
similar, at 151.1% and 155.0%, respectively. For DHA,
the intake for the rTG group was twice that of the EE
group; however, the whole blood percentage increase in
DHA was 44.6% for the rTG group but only 12.9% for
EE, an almost fourfold difference. The PL group intake
of EPA was similar to that of the TG group (150 and
180 mg/day, respectively) and the mean whole blood
EPA percentage increases were almost identical, at 34.9%
and 35.7%, respectively. Finally, the DHA intake of the
EE and TG groups were only 3.6% apart, at 228 and
220 mg/day, respectively, yet the mean whole blood per-
centage changes were 12.9% and 18.9% respectively, an
almost 50% difference.
The data was also analysed for gender differences, and
some modest differences were noted. For example, the
EPA% change between the EE and the TG supplements
was statistically significant for females, but not quite sig-
nificant for males (p-value of <0.0001 and 0.0693, respect-
ively). Similarly, both the DHA change and% change,
when comparing the rTG and TG supplements, were sig-
nificantly different for females (p-value of 0.0002 and
0.0182, respectively), whereas for males these same vari-
ables were not significantly different (p-value of 0.0736
and 0.2753, respectively). Otherwise, in pair-wise compari-
sons, statistically significant changes were similar in males
and females, for EPA and DHA.
Extrapolation of data for a 1,000 mg intake
Given the differences in intake levels for the four supple-
ments, an attempt was made to extrapolate the data for
an intake of 1,000 mg/day of each omega-3 fatty acid.
For three of the four supplements in this trial, some sub-
jects actually experienced negative results from Day 0 to
Day 28, i.e. the level of one or more of their long-chain
omega-3 fatty acids actually decreased. For example, al-
though none of the subjects consuming the rTG and the
EE products experienced a decrease in EPA levels from
Day 0 to Day 28, eight of the subjects in the krill oil PL
group, and six consuming the TG supplement did ex-
perience a drop in EPA levels. Similarly, the blood DHA
levels for a number of subjects in the EE, PL and TG
groups decreased from Day 0 to Day 28 (11, 13 and 7
subjects, respectively). All of the capsule counts for these
subjects indicated full or close-to-full compliance; how-
ever, capsule count is not always the best indicator of
compliance. In this trial, using % change in blood EPA
levels (often a more accurate measure of compliance)
was not appropriate because of the great variation in the
Table 2 Values for selected fatty acids and fatty acid calculated ratios* on Day 0 and Day 28, by treatment
Treatment Visit AA EPA DPA DHA EPA + DHA AA:EPA EPA + DPA + DHA ω-3 FA ω-6 FA ω-3:ω-6 ω-6:ω-3
rTG
Day 0 12.217 ± 2.091 1.175 ± 0.438 1.344 ± 0.303 2.997 ± 0.672 4.172 ± 0.923 11.886 ± 4.901 5.516 ± 0.983 6.333 ± 1.063 43.156 ± 3.999 0.148 ± 0.029 7.022 ± 1.484
Day 28 11.666 ± 1.854 2.644 ± 0.717 1.595 ± 0.290 4.174 ± 0.657 6.818 ± 1.190 4.738 ± 1.523 8.418 ± 1.165 9.140 ± 1.239 40.530 ± 4.168 0.228 ± 0.043 4.516 ± 0.771
EE
Day 0 11.550 ± 2.284 1.065 ± 0.367 1.356 ± 0.287 3.063 ± 0.844 4.128 ± 1.004 12.164 ± 4.938 5.487 ± 1.168 6.242 ± 1.193 41.911 ± 4.634 0.151 ± 0.034 6.991 ± 1.674
Day 28 11.235 ± 2.129 2.449 ± 0.858 1.544 ± 0.298 3.318 ± 0.763 5.767 ± 1.249 5.058 ± 1.783 7.311 ± 1.311 8.067 ± 1.289 40.339 ± 4.102 0.201 ± 0.033 5.103 ± 0.853
PL
Day 0 11.57 ± 2.134 1.147 ± 0.463 1.352 ± 0.291 3.123 ± 0.759 4.269 ± 0.968 11.576 ± 5.007 5.628 ± 1.088 6.428 ± 1.203 42.300 ± 5.157 0.154 ± 0.036 6.784 ± 1.341
Day 28 11.316 ± 1.897 1.440 ± 0.487 1.502 ± 0.269 3.317 ± 0.728 4.756 ± 0.942 8.836 ± 3.449 6.258 ± 1.045 6.951 ± 1.075 40.849 ± 4.168 0.171 ± 0.030 6.002 ± 11.04
TG
Day 0 11.698 ± 2.667 1.131 ± 0.426 1.446 ± 0.354 3.061 ± 0.763 4.192 ± 0.942 11.568 ± 4.508 5.638 ± 1.098 6.396 ± 1.137 41.791 ± 5.499 0.155 ± 0.029 6.687 ± 1.177
Day 28 11.345 ± 1.826 1.425 ± 0.465 1.460 ± 0.291 3.508 ± 0.640 4.932 ± 0.865 8.963 ± 4.037 6.388 ± 0.850 7.148 ± 1.007 41.088 ± 3.135 0.175 ± 0.032 5.872 ± 1.002





















Figure 1 Mean levels of EPA + DHA for four supplement groups at Day 0 and Day 28.
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150 mg/day to a high of 756 mg/day). Thus, results were
taken at face value, assuming full compliance.
Because an extrapolation calculation involving a
negative result (i.e. decrease in the level of an omega-3
biomarker from Day 0 to Day 28) will merely increase
its “negativity”, negative results were dealt with in two
different ways: removal of negative values entirely, or
allocating all negative values at 0. Table 4 illustrates
these extrapolated results.Potential for cardiovascular disease risk reduction
One of the biomarkers employed to assess the potential
ω-3 FA effect on CVD disease risk reduction was the
whole blood OmegaScore™. This test is a combined
measure of EPA +DPA +DHA, and high vs. low quartiles
are linked to low or high risk of sudden death [32]. From
this biomarker, correlation equations have been formu-
lated to provide three other biomarker scores, the Omega-
3 Serum Equivalence Score (ω-3 SES), from which heart
disease risk reduction may be extrapolated [33], the EPA
+DHA Serum Equivalence Score (E + DSES), from which
risk of death from fatal ischemic heart disease may be ex-
trapolated [34], and the Omega-3 Red Blood Cell Equiva-
lence Score (ω-3RBCES), also known as the Omega-3
Index, from which protection against sudden myocardial
infarction may be estimated [35].Using the directly measured OmegaScore® results, the
three associated scores were calculated for each subject,
and the risk level for each subject was given a risk rank-
ing based on the cut-off points for each of the four
parameters listed previously. These cut-off points are
presented in Table 5. Each subject’s risk ranking change
from Day 0 to Day 28 was rated as Good, Neutral or
Poor, based on the following:
Good: Subject’s risk ranking changed from a higher risk
to a lower risk, e.g. high risk to moderate risk, or
moderate risk to low risk, etc.
Neutral: Subject’s initial risk ranking of low or
moderate risk did not change from Day 0 to Day 28.
Poor: Subject’s risk ranking changed from a lower risk
to a higher risk, or, in the case of an initial high or very
high risk, did not change from Day 0 to Day 28.
Table 6 illustrates the assessment of the four supple-
ments, vis-à-vis these ratings. From Tables 5 and 6, it
should be noted that the EPA + DHA Serum Equivalence
Score cut-off point from moderate to low risk is rela-
tively lower than for the other calculated biomarkers,
with the result that many of the subjects’ initial EPA +
DHA Serum Equivalence Scores were already higher
than the low risk cut-off point. This meant that the po-
tential for positive change in this biomarker was limited;
Table 3 Change and percentage change (in% by weight) in selected fatty acids and fatty acid ratios of interest between Day 0 and Day 28, by treatment, with
statistical significance
Treatment
AA EPA DPA DHA EPA + DHA AA:EPA EPA + DPA + DHA ω −3 FA ω −6 FA ω-3:ω-6 Ratio ω-6:ω-3 Ratio
Δ % Δ Δ % Δ Δ % Δ Δ % Δ Δ % Δ Δ % Δ Δ % Δ Δ % Δ Δ % Δ Δ % Δ Δ % Δ
rTG mean −0.551 −3.27 1.469 151.1*** 0.251 22.8** 1.177 44.6*** 2.646 69.8*** −7.148 −56.7*** 2.903 56.9*** 2.807 47.5*** −2.626 −5.78** 0.080 57.6*** −2.507 −34.4***
rTG SD 1.770 14.60 0.691 102.69 0.312 28.01 0.628 36.49 1.150 44.37 4.271 13.62 1.218 34.63 1.244 28.671 3.889 8.970 0.033 30.403 1.342 11.366
EE mean −0.316 −0.98 1.384 155.0*** 0.189 17.0* 0.255 12.90 1.638 47.5*** −7.107 −54.3*** 1.824 39.4*** 1.826 33.9*** −1.572 −3.200 0.050 37.4*** −1.888 −24.7***
EE SD 2.207 19.54 0.847 123.65 0.273 24.74 0.656 31.80 1.365 49.05 4.745 18.13 1.521 41.46 1.497 34.923 4.153 9.537 0.029 28.093 1.413 13.871
PL mean −0.260 −0.73 0.293 34.9* 0.150 14.5* 0.194 8.93 0.487 14.5* −2.740 −17.2* 0.637 13.5*** 0.523 10.200 −1.450 −2.720 0.017 13.2* −0.782 −10.2*
PL SD 1.876 16.32 0.528 45.48 0.290 24.65 0.512 20.08 0.874 23.43 4.109 34.78 0.974 19.14 1.131 18.698 4.559 10.214 0.024 16.039 0.921 12.839
TG mean −0.353 0.24 0.294 35.7** 0.014 4.37 0.447 18.9* 0.740 21.3** −2.606 −17.9* 0.751 16.6*** 0.752 14.2** −0.703 −0.628 0.020 13.4* −0.815 −11.4**
TG SD 2.206 20.22 0.493 43.34 0.301 21.60 0.596 27.34 0.866 25.65 4.249 34.61 1.118 23.20 1.161 20.229 4.509 10.030 0.020 12.827 0.791 11.331





















Figure 2 Mean percentage change in EPA, DHA and EPA + DHA levels from Day 0 to Day 28, with statistical comparisons among the
four comparator products.
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out this biomarker included, and they are also presented
in Table 6. At the daily doses directed by the manufac-
turer, the concentrated triglyceride (rTG) supplement
was most successful in reducing risk across the parame-
ters of OmegaScore™, Omega-3 Serum Equivalence
Score and the Omega-3 Red Blood Cell Equivalence
Score, with the ethyl ester supplement being quite simi-
lar, and the krill and non-concentrated triglyceride sup-
plements being less successful.
As noted previously, a “neutral” rating was given to
subjects whose risk category at Day 0 was moderate or
low, and whose risk category had not changed by Day
28. However, it could be argued that for those subjects
who were initially categorised as low-risk, no change by
Day 28 could be considered “good” rather than “neutral”,
given that there is no better category than low-risk, and
therefore no improvement in that category is possible. In
addition, these subjects did not change from the low-risk
category to a higher-risk one. Table 7 is a representation
of the same calculations as before, except that subjects
who were categorised as low-risk initially, and who
remained low-risk at Day 28, were given a “good” rating
than a “neutral” rating. This readjustment did not alter the
overall rankings of the four supplements, although, asexpected, it did increase the number of “good” responses
for each supplement.
Discussion
From the results, it has clearly been shown that the con-
centrated rTG fish oil supplement, at the prescribed
daily dose, produces a greater increase in whole blood
ω-3FAs than the EE fish oil supplement, the krill oil PL
supplement and the salmon oil TG supplement, at their
prescribed doses. Both the EPA + DHA combination and
DHA alone exhibited the greatest increase with the rTG
supplement, and the greatest decrease in ω-6 FAs. For
the increase in EPA alone, the concentrated TG fish oil
supplement is similar to the EE fish oil supplement in
this regard, but much higher that the krill oil PL and sal-
mon oil TG supplements. The percentage change in
EPA for the concentrated rTG fish oil and EE fish oil
supplement is more than four times that of the krill oil
and salmon oil supplements.
For DHA, this increase in the concentrated rTG fish
oil supplement is illustrated effectively in Table 3,
where the percentage increase in DHA for the concen-
trated rTG fish oil product is 44%, which is highly sig-
nificant and much greater than for any of the other
supplements. Only the other TG supplement, derived
Table 4 Extrapolated results for an intake of 1,000 mg/day of EPA or DHA
All data included EPA DHA
TRT Statistic %Δ Extrapolated % Δ %Δ Extrapolated % Δ
rTG
Mean 151 232 45 99
SD 103 158 36 81
EE
Mean 155 205 13 57
SD 124 164 32 139
PL
Mean 35 232 9 99
SD 45 303 20 223
TG
Mean 36 198 19 86
SD 43 241 27 124
Negative data deleted* EPA DHA
TRT Statistic %Δ Extrapolated % Δ %Δ Extrapolated % Δ
rTG
Mean 151 232 45 99
SD 103 158 36 81
EE
Mean 155 205 26 113
SD 124 164 32 141
PL
Mean 53 354 22 240
SD 36 242 16 180
TG
Mean 50 278 27 123
SD 33 185 25 115
Negative data allocated 0 value** EPA DHA
TRT Statistic %Δ Extrapolated % Δ %Δ Extrapolated % Δ
rTG
Mean 151 232 45 99
SD 103 158 36 81
EE
Mean 155 205 17 74
SD 124 164 29 125
PL
Mean 40 266 13 142
SD 39 260 16 182
TG
Mean 41 226 21 96
SD 36 200 25 113
*Any subject data in which the EPA or DHA values decreased from Day 0 to Day 28 were deleted from the extrapolation calculations for the appropriate omega-3
fatty acid.
**Any subject data in which the EPA and/or DHA values decreased from Day 0 to Day 28 were given a value of zero (0) for the omega-3 fatty acid(s) in question.
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at a much lower level of significance than the concen-
trated rTG fish oil supplement, i.e. P = 0.0137 vs. p <
0.0001, respectively (data not shown). In order of best
to worst, in terms of significant beneficial changes in
ω-3FA biomarkers, in combinations and in calculated ra-
tios, the ranking is concentrated rTG fish oil > EE fish oil >Table 5 Cut-off points for four biomarkers associated with ca
Biomarker Risk condition
OmegaScore™ (EPA + DPA + DHA) Sudden death
ω-3 Serum Equivalence Score Heart disease
EPA + DHA Serum Equivalence Score Fatal ischemic heart disease
ω-3 Red Blood Cell Equivalence Score Myocardial infarctionSalmon oil TG >Krill Oil PL. Both the krill oil and the sal-
mon oil TG produced a smaller increase in blood levels of
most of the ω-3FA biomarkers of interest, when compared
to concentrated rTG fish oil and EE fish oil.
However, given the considerable variability in the sup-
plement doses given to trial subjects, all of the above is
to be expected, i.e. the higher the dose, the greater therdiovascular risk
Very high risk High risk Moderate risk Low risk
<4.3 4.3-5.1 5.1-6.1 >6.1
N/A <5.1 5.1-7.2 >7.2
N/A <3.5 3.5-4.5 >4.5
N/A <5.2 5.2-8.0 >8.0
Table 6 Number of subjects who rated as Good, Neutral or Poor in terms of CVD risk reduction, from Day 0 to Day 28
Type of FA Score OS™(EPA + DPA + DHA) ω-3 SES E + DSES ω-3 RBCES Total Total minus E + DSES
rTG Good 26 26 9 27 88 79
Concentrated Neutral 6 6 23 5 40 17
Triglyceride Poor 0 0 0 0 0 0
EE Good 19 23 10 16 68 58
Ethyl ester Neutral 12 6 21 15 54 33
Poor 1 3 1 1 6 5
PL Good 14 12 7 10 43 36
Phospho- Neutral 15 14 23 19 71 48
lipid (krill) Poor 3 6 2 3 14 12
TG Good 18 12 7 9 46 39
Triglyceride Neutral 10 15 25 21 71 46
Poor 4 5 0 2 11 11
OS™: OmegaScore™; ω-3 SES: Omega-3 Serum Equivalence Score; E + DSES: EPA + DHA Serum Equivalence Score; ω-3 RBCES: Omega-3 Red Blood Cell Equivalence
Score (Omega-3 Index).
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compare the four supplements, the results were extrapo-
lated for an intake of 1,000 mg, but this was less than
successful, given the considerable number of subjects in
some of the groups whose blood levels of some omega-3
fatty acids decreased from Day 0 to Day 28. For example,
the krill oil EPA extrapolated increase was 232% with all
subjects’ data included, 354% with all negative values de-
leted, and 266% with all negative values replaced with a
zero. However, neither of these latter two values is any
more accurate that the value with all data included, as
the fact remains that in 8 of 35 subjects in the PL group,
blood levels of EPA actually decreased in value during
the supplementation period. Because of the difficultiesTable 7 Adjusted* number of subjects who scored Good, Neu
Day 28
Type of FA Score OS™(EPA + DPA + DHA) ω-3 SES
rTG Good 32 30
Concentrated Neutral 0 2
Triglyceride Poor 0 0
EE Good 30 26
Ethyl ester Neutral 0 3
Poor 2 3
PL Good 24 15
Phospho- Neutral 5 11
lipid (krill) Poor 3 6
TG Good 26 17
Triglyceride Neutral 2 10
Poor 4 5
OS™: OmegaScore™; ω-3 SES: Omega-3 Serum Equivalence Score; E + DSES: EPA + D
Equivalence Score.
*“neutral” numbers have been adjusted to exclude subjects whose initial ranking fo
Day 0 to Day 28. These subjects have been re-rated as “good”.encountered in data extrapolation, i.e. the inaccuracies
inherent in the methodology, given the negative results
for some subjects, a statistical analysis of this data was
not considered to be warranted.
Given the high supplement levels of EPA in the rTG
and EE groups, relative to the PL and TG groups, (650
and 756 vs. 150 and 180 mg/day, respectively) one could
assume that these groups’ blood EPA values should have
increased, and this was the case; indeed, none of these
subjects reduced EPA levels, and this tends to reinforce
the belief of good compliance with the trial protocol.
That being the case, there is no reason to believe that
these same subjects were any less compliant when con-
suming the other two products in this crossover trial,tral or Poor in terms of CVD risk reduction, from Day 0 to
E + DSES ω-3 RBCES Total Total minus E + DSES
32 27 121 89
0 5 7 7
0 0 0 0
31 16 103 72
0 15 18 18
1 1 7 6
30 10 79 49
0 19 35 35
2 3 14 12
30 9 82 52
0 21 33 33
2 2 13 11
HA Serum Equivalence Score; ω-3 RBCES: Omega-3 Red Blood Cell
r any of the biomarkers was low risk, and whose ranking did not change from
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in different and random order, i.e. they were not suffer-
ing from “intake fatigue” towards the end of the study,
given that at least some of them consumed the latter
two products (PL and TG) at the beginning or middle of
the study. Thus, one may conclude that the negative
values obtained for the EE, PL and TG groups are an ac-
curate reflection of what transpired in the trial.
One explanation of the negative results for some of
the subjects in the latter two groups (PL and TG) is the
possibility that these subjects were consumers of a sig-
nificant amount of fish prior to the study, and that the
amount of EPA and DHA in the supplements for these
groups was insufficient to match their previous intake
from food, prior to supplementation. In future designs,
it would be useful to ask subjects to refrain from con-
suming any fish products for an appropriate amount of
time prior to study onset, and to supplement all subjects
with a nominal amount of EPA and DHA for a run-in
period prior to the commencement of the trial.
Although only small differences in gender compari-
sons were noted, the number of subjects in each group
was small, i.e. 18 males and 17 females, and this may
have been inadequate for accurate statistical comparison,
such that it was insufficiently powered to detect gender
differences. In order to more fully examine possible gen-
der differences, future recruitment of a larger number of
subjects in each group would permit more in-depth ana-
lysis of possible gender differences following omega-3
supplementation.
Of greater interest to the general population, and par-
ticularly to the significant number of North Americans
at risk for cardiovascular disease, are the effects of sup-
plementation on CVD risk reduction. The results for the
measured and derived biomarkers specifically related to
aspects of cardiovascular disease risk reduction clearly il-
lustrate that the consumer must give careful consider-
ation to the type and dosage of supplement they choose.
For example, fewer than half of the subjects who con-
sumed the krill oil supplement, at the recommended
dosage, reduced the risk for sudden death, heart disease,
death from fatal ischemic heart disease and sudden myo-
cardial infarction, according to the measured and calcu-
lated indices. The majority experienced no benefit, and a
few actually experienced a possible increase in risk.
Conversely, the vast majority of subjects who consumed
the concentrated rTG fish oil were projected to reduce
their risk of the aforementioned CVD-related conditions,
except for the risk of death from fatal ischemic heart dis-
ease, where most of the subjects consuming each of the
supplements experienced no change in this risk. Results
for the EE fish oil group were somewhat better than for
the krill oil PL or TG fish oil group, but not as good as
those of the concentrated fish oil rTG group.The fatty acid analyses employed in this study did not in-
clude the isolation of serum or plasma phospholipids, or of
red blood cell phospholipids. These analyses would more
fully reflect the concentrations of ω-3 FAs available for fur-
ther metabolism. It is at this level of metabolism that ω-3
FAs exhibit their greatest beneficial effects; for example, as
anti-inflammatory omega-3 prostaglandin precursors, they
compete metabolically with pro-inflammatory ω-6 precur-
sors [36-38]. In any future study, it would be useful to
examine the concentrations of ω-3 FAs in membrane
phospholipids, vis-à-vis serum phospholipid fatty acid ana-
lyses. Also, levels of lipid peroxides in supplements and in
subjects’ plasma samples would be useful as an indicator
of any deterioration of long chain fatty acids in the
supplements.
In addition, a head-to-head comparison of the supple-
ments utilised in this trial, at equivalent doses of EPA and
DHA, would be useful in determining their relative bio-
availability and their efficacy in increasing blood levels of
omega-3 fatty acids, and in reducing CVD risk. In many
omega-3 clinical trials, compliance is measured both by
pill count before and after supplementation, and by per-
centage increase in blood EPA levels post-consumption. In
this study, only the former was possible, as EPA levels
were highly reliant on the level of EPA supplementation.
In a study with equivalent doses of EPA, percentage
change in EPA post-supplementation could be utilised
to further verify compliance. Furthermore, although
compliance by pill count was excellent, there is no way
to verify if subjects did indeed fully comply with the
protocol, and some of the results may have been a result
of lack of compliance, rather than the relative efficacy of
the supplement per se.
A statistical assessment of the order of treatment
showed no effect of treatment order on the results. Like-
wise, there were no statistical differences among baseline
levels of EPA and DHA after each washout period. None-
theless, it would be useful, in future studies, to measure
other biomarkers in addition to levels of omega-3 fatty
acids, for example levels of carrier proteins, receptors, etc.,
in order to ensure that absence of any carry-over effect
after each washout period. In addition, diet records and/or
food frequency questionnaires during washout periods
would be useful in determining both background diet and
omega-3 intake of subjects. Alternatively, subjects might
be given a list of foods (e.g. fish and fish products) and
supplements that would be forbidden from consumption
during the washout periods, as this would facilitate equal-
ity of baseline levels of omega-3 fatty acids at the begin-
ning of each test period.
Conclusion
Current research indicates several different roles for the
individual ω-3 FAs in the body [39,40], such that the
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supplementation, and the benefits that ensue from that
supplementation, may depend upon the purpose of the
supplementation for each individual, i.e. patients with a
particular condition or disease vs. healthy individuals. Re-
searchers have reported that relative amounts of EPA and
DHA in a supplement differentially confer beneficial ef-
fects [41-43]. It may be that a small increase in a given ω-
3 FA may be sufficient for some individuals, whereas a lar-
ger increase may be necessary for patients with specific
conditions. This study has shown that for segments of the
population hoping to reduce their risk of developing ele-
ments of CVD, a judicious decision regarding the type and
daily dose of ω-3 supplement will be important. It is clear
that not all ω-3 supplements are created equal, at least in
terms of CVD risk reduction.
Subjects and methods
Subjects
Beginning in May of 2012, a total of 35 healthy participants,
17 females and 18 males, were recruited for the trial via
newspaper and social media advertisements in Guelph, On-
tario, Canada. The mean age of the group was 34.5 years,
with a range of 19 to 60 years. Major inclusion criteria was
good health, and exclusion criteria included having taken
omega-3 supplements in the previous 3 months, consum-
ing fish on a regular basis (more than one serving per
week), any fish or seafood allergy, the diagnosis of any med-
ical illness or conditions, and any gastro-intestinal insuffi-
ciency. This study was conducted in accordance with the
current version of GCP as defined in the International Con-
ference of Harmonization. Written informed consent was
obtained prior to participation in the study, and the in-
formed consent form (ICF) followed the principles defined
by the FDA in US 21 CFR part 50 and the ICH Guidelines.
The ICF, study protocol and any amendments were ap-
proved by an independent Research Ethics Board prior to
the commencement of the study. The last patient, last visit
was in June of 2013.Table 8 Per capsule and total daily dosage composition of fo
TRT Product EPA & DHA per capsule* Te
rTG
Nordic Naturals ProOmega® 325 mg EPA 32
Triglyceride 225 mg DHA 22
EE
Minami MorEPA® 756 mg EPA 77
Platinum Ethyl Ester 228 mg DHA 23
PL
Source Naturals ArcticPure® 75 mg EPA 7
Krill Oil Phospholipid 45 mg DHA. 46
TG
New Chapter
Wholemega® Salmon 90 mg EPA 9
Oil Triglyceride 110 mg DHA 10
*As listed on manufacturer’s label.Study design
This was a single centre, open-label, randomized, cross-
over comparator study. Eligible participants were ran-
domly assigned to consume one of four products for a
period of 4 weeks, followed by a 4-week washout period,
and this schedule of four weeks on, four weeks off con-
tinued until all participants had consumed each product
for a 4-week period. The randomization of the order of
treatment substances was generated using an Internet
program (http://www.randomization.com) and the pro-
cedure was verified using SAS© statistical software at
the University of Guelph. Subjects were requested to
consume the dose of each supplement that was pre-
scribed on the bottle label. The ω-3 FA content of the
four supplements is presented in Table 8.
Venipuncture blood samples were collected into K-
EDTA-anticoagulated tubes at the beginning and end of
each 4-week period, and analysed for whole blood fatty
acids. Height, weight and blood pressure were measured
at each time-point, Body Mass Index (BMI) was calcu-
lated, and protocol compliance was measured by capsule
count at the end of each 4-week consumption period.
The primary outcome measures were change in whole
blood levels of EPA, DHA, and EPA +DHA from Day 0
to Day 28. Secondary outcome measures were change in
docosapentaenoic acid (DPA) level and in Omega-3:
Omega-6 Ratio from Day 0 to Day 28.
Whole blood fatty acid analysis
The methodology involved quantification of fatty acids
by gas chromatography flame ionization detection (GC-
FID). Whole blood fatty acids were methylated with
acidified methanol, followed by separation of the ana-
lytes and delivery of the sample to the flame ionization
detector for ionization and detection by the GC system.
Fatty acid methyl esters (FAMEs) were separated on a
capillary column based on their boiling points. The efflu-
ent from the GC column passed through an FID flame
(FID consists of a hydrogen/air flame and a collectorur comparator products (CP)
















9.5 mg DHA DHA: 220 mg
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duces ions. The ions were collected on a biased elec-
trode and produced an electrical signal. The resulting
current was amplified to yield the output signal, which
was observed as a peak in the chromatogram. The FID
is extremely sensitive with a large dynamic range. Quan-
tification of fatty acid methyl esters was based on one-
point calibration curves that were generated for all 25
analytes. Concentration of each fatty acid in an unknown
sample was converted into mass by multiplying the con-
centration (μM) with the molecular weight (g/mol) and
volume of the sample (injection volume, 1 μl). The sum
of all analytes (g) in a sample was then used to establish
the fraction of FAMEs as% weight.
Statistics
A power analysis indicated that 30 subjects would be re-
quired to detect a difference of 0.24% by weight of total
EPA, assuming a variance error of 0.33% by weight, a
p-value of 0.05 and power of 80%. SAS 9.3 was used
for statistical analysis (SAS Institute Inc., Cary, NC).
ANOVA for repeated measures (PROC MIXED) was
the statistical method used to determine if there were
any significant differences from Day 0 to Day 28, for
each of the four supplements. To determine if the change
from Day 0 to Day 28 was statistically different among
the four supplements, PROC LSMEANS, with Tukey’s
adjustment for multiple comparisons was employed. All
data were also checked for normality, and for homogen-
eity of variance using Shapiro-Wilks and Brown-Forsyth
testing, respectively. All of the directly-measured bio-
marker results were normally-distributed, as were all of
the calculated biomarkers, except for the EPA + DHA
percentage change. However, there was homogeneity of
variance for both the directly-measured and the calcu-
lated biomarkers, including EPA+DHA percentage change;
thus, parametric statistical methods were considered
appropriate.
Abbreviations
AA: Arachidonic Acid; BMI: Body Mass Index; BP-D: Blood Pressure - Diagnostic;
BP-S: Blood Pressure-Systolic; CRF: Case Report Form; RTG: Comparator Product
A- Nordic Naturals® ProOmega®; EE: Comparator Product B – Minami MorEPA®
Platinum; PL: Comparator Product C – Source Naturals ArcticPure®;
TG: Comparator Product D – New Chapter Wholemega-3®;
DHA: Docosahexaenoic Acid; DPA: Docosapentaenoic Acid; EE: Ethyl Ester;
EPA: Eicosapentaenoic Acid; FAMEs: Fatty Acid Methyl Esters; FA(s): Fatty Acid(s);
FDA: Food and Drug Administration; GC-FID: Gas Chromatograph- Flame
Ionisation Detection; HT: Height; ICH: International Conference on
Harmonization; μmol: Micromole; Mg: Milligram; NDI: Nutrasource Diagnostics
Incorporated; ω-3 FA: Omega-3 Fatty Acids; PL: Phospholipid; SAS: Statistical
Analysis System; SD: Standard Deviation; SOP: Standard Operating Procedure;
TG: Triglycerides (Triacylglycerol); WT: Weight; ω-3:ω-6: Omega-3:Omega-6 Ratio;
ω-6:ω-3: Omega-6:Omega-3 Ratio.
Competing interests
In the past five years none of the co-authors has received reimbursements,
fees, funding, or salary from an organization that may in any way gain or lose
financially from the publication of this manuscript, either now or in thefuture. All three co-authors are employed by Nutrasource Diagnostics Inc., a
Contract Research Organisation based in Guelph, Ontario, Canada. Nordic
Naturals contracted NDI to design and implement this clinical trial, and they
funded the entire trial, including provision of all four of the comparator
products tested in this trial, and including any publication costs. NDI has no
financial relationship with Nordic Naturals, other than as a third-party CRO
being contracted to perform a clinical trial at arm’s length from the sponsor,
and being paid for this work. NDI owns the trademark of the OmegaScore™
test. The OmegaScore™ was utilized in this trial as only a diagnostic test for
cardiovascular risk from omega-3 fatty acid levels. The study was not
designed in any way to support or market the use of the OmegaScore™.
None of the co-authors hold any stocks or shares in an organization that
may in any way gain or lose financially from the publication of this
manuscript, either now or in the future.
None of the co-authors hold or are currently applying for any patents relating
to the content of the manuscript. They have not received reimbursements, fees,
funding, or salary from an organization that holds or has applied for patents
relating to the content of the manuscript.
None of the co-authors have any other financial competing interests.
There are no non-financial competing interests (political, personal, religious,
ideological, academic, intellectual, commercial or any other) to declare in
relation to this manuscript.Authors’ contributions
ML co-designed the trial, collated the results, completed a final report and
wrote this manuscript. CC was the key researcher in the operation and
completion of the clinical trial. She enrolled participants, assigned them to
interventions, and followed them throughout the trial. WR was co-designer
of the trial. A staff person from NDI who was not involved in the clinical trial
generated the randomization sequence. All authors read and approved the
final manuscript.
Received: 28 February 2014 Accepted: 17 June 2014
Published: 21 June 2014References
1. Schwalfenberg G: Omega-3 fatty acids: their beneficial role in
cardiovascular health. Can Fam Physician 2006, 52:734–740.
2. Wu JHY, Lemaitre RN, King IB, Song X, Sacks FM, Rimm EB, Heckbert SR,
Siscovick DS, Mozaffarian D: Association of plasma phospholipid long-
chain omega-3 fatty acids with incident atrial fibrillation in older
adults: the cardiovascular health study. Circulation 2012,
125:1084–1093.
3. Oh R: Practical applications of fish oil (ω-3 fatty acids) in primary care.
J Am Board Fam Pract 2005, 18:28–36.
4. Bucher HC, Hengstler P, Schindler C, Meier G: N-3 polyunsaturated fatty
acids in coronary heart disease: a meta-analysis of randomized
controlled trials. Am J Med 2002, 112:298–304.
5. Lopez LB, Kritz-silverstein D, Barrett-Connor E: High dietary and plasma
levels of the omega-three fatty acid docosahexaenoic acid are associ-
ated with decreased dementia risk: the Rancho Bernardo study. J Nutr
Health Aging 2011, 15(1):25–31.
6. Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, Salem N
Jr, Stedman M, on behalf of the MIDAS Investigators: Beneficial effects of
docosahexaenoic acid on cognition in age-related cognitive decline.
Alzheimers Dement 2010, 6:456–464.
7. Navqi AZ, Buettner C, Phillips RS, David RB, Mukamel KJ: n-3 fatty acids and
periodontitis in US adults. J Am Diet Assoc 2010, 110:1669–1675.
8. Lee YH, Bae SC, Song GG: Omega-3 polyunsaturated fatty acids and the
treatment of rheumatoid arthritis: a meta-analysis. Arch Med Res 2012,
43(5):356–362.
9. Dawczynski C, Hackermeier U, Viehweger M, Strange R, Springer M, Jahreis G:
Incorporation of n-3 PUFA and γ-linolenic acid in blood lipids and red
blood cell lipids together with their influence on disease activity in patients
with chronic inflammatory arthritis–a randomized controlled human inter-
vention trial. Lipids Health Dis 2011, 10:130–138.
10. United States Department of Agriculture; Department of Health and Human
Services: Dietary Guidelines for Americans, 2010. U.S Government printing
office Washington, DC, USA, 2010.
Laidlaw et al. Lipids in Health and Disease 2014, 13:99 Page 13 of 13
http://www.lipidworld.com/content/13/1/9911. Kris-Etherton PM, Harris WS, Appel LJ, Committee FTN: Fish consumption,
fish oil, omega-3 fatty acids, and cardio-vascular disease. Circulation 2002,
106:2747–2757.
12. Harris WS, Mozaffarian D, Lefevre M, Toner CD, Columbo J, Cunnane SC,
Holden JM, Klurfeld DM, Morris MC, Whelan J: Towards establishing dietary
reference intakes for eicosapentaenoic and docosahexaenoic acids.
J Nutr 2009, 139:804S–819S.
13. Agricultural Research Service, United States Department of Agriculture
(USDA): USDA National Nutrient Database for Standard Reference,
Release 25. 2012, USDA Washington, DC, USA.
14. Raatz SK, Silverstein JT, Jahns L, Picklo MJ: Issues of fish consumption for
cardiovascular disease risk reduction. Nutrients 2013, 5(4):1081–1097.
15. Sekikawa A, Steingrimdottir L, Ueshima H, Shin C, Curb JD, Evans RW,
Hauksdottir AM, Kadota A, Choo J, Masaki K, Thorsson B, Launer LJ, Garcia
ME, Maegawa H, Willcox BJ, Eiriksdottir G, Fujiyoshi A, Miura K, Harris TB,
Kuller LH, Gudnason V: Serum levels of marine-derived n-3 fatty acids in
Icelanders, Japanese, Koreans, and Americans – A descriptive epidemio-
logic study. Prostaglandins Leukot Essent Fatty Acids 2012, 87:11–16.
16. Giraldi G, De Luca dÀlessandro E: Dietary habits in Italy: the importance of
the Mediterranean diet. Ann Ig 2012, 24(4):311–317.
17. Cardoso C, Lourenco H, Costa S, Goncalves S, Nunes ML: Survey into the
seafood consumption preferences and patterns in the Portuguese
population. Gender and regional variability. Appetite 2013, 54:20–31.
18. Calderon-Garcia JF, Moran JM, Roncero-Martin R, Rey-Sanchez P, Rodriguez-
Velasco FJ, Pedrera-Zamorano JD: Dietary habits, nutrients and bone mass
in Spanish premenopausal women: the contribution of fish to better
bone health. Nutrients 2012, 5(1):10–22.
19. Guili C, Papa R, Mocchegiani M, Marcellini F: Dietary habits and ageing in a
sample of Italian older people. J Nutr Health Aging 2012, 16(10):875–879.
20. www.crnusa.org Council for Responsible Nutrition contact: Nancy Stewart:
Consumer confidence in supplements remains at two year high: New
Survey Results Confirm: Two-thirds of U.S. adults take supplements.
Washington, D.C. September 20, 2013.
21. Schulthess G, Lipka G, Compassi S, Boffelli D, Weber FE, Paltauf F, Hauser H:
Absorption of monoacylglycerols by small intestinal brush border
membrane. Biochemistry 1994, 33:4500–4508.
22. Lawson L, Hughes B: Human absorption of fish oil fatty acids as
triglycerides, free acids, or ethyl esters. Biochem Biophys Res Commun
1988, 152(1):328–335.
23. el Boustani S, Colette C, Monnier L, Descomps B, Crastes de Paulet A,
Mendy F: Eternal absorption in man of eicosapentaenoic acid in different
chemical forms. Lipids 1987, 22(10):711–714.
24. Beckermann B, Beneke M, Seitz I: Comparative bioavailability of
eicosapentaenoic acid and docosahexaenoic acid from triglycerides, free
fatty acids and ethyl esters in volunteers. Arzneimittelforschung 1990,
40(6):700–704.
25. Wakil A, Mir M, Mellor DD, Mellor SF, Atkin SL: The bioavailability of
eicosapentaenoic acid from reconstituted triglyceride fish oil is higher
than that obtained from the triglyceride and monoglyceride forms.
Asia Pac J Clin Nutr 2010, 19(4):499–505.
26. Dyerberg J, Madsen P, Moller JM, Aardstrup I, Schmidt EB: Bioavailability of
marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids
2010, 83(3):137–141.
27. Milte CM, Coates AM, Buckley JD, Hill AM, Howe PR: Dose-dependent
effects of docosahexaenoic acid-rich fish oil on erythrocyte docosahex-
aenoic acid and blood lipid levels. Br J Nutr 2008, 99(5):1083–1088.
28. Conquer JA, Holub BJ: Effect of supplementation with different
doses of DHA on the levels of circulating DHA as non-esterified
fatty acid in subjects of Asian Indian background. J Lipid Res 1998,
39(2):286–292.
29. Mozaffarian D, Lemaitre RN, King IB, Song X, Huang H, Sacks FM, Rimm EB,
Wang M, Siscovick DS: Plasma phospholipid long-chain omega-3 fatty
acids and total and cause-specific mortality in older adults: the cardio-
vascular health study. Ann Int Med 2013, 158(7):515–525.
30. Schuchardt JP, Schneider I, Meyer H, Neubronner J, von Schacky C,
Hahn A: Incorporation of EPA and DHA into plasma phospholipids in
response to different omega-3 fatty acid formulations – a compara-
tive bioavailability study of fish oil vs. krill oil. Lipids Health Dis 2011,
10(145):1–7.
31. Davidson MH, Johnson J, Rooney MW, Kyle ML, Kling DF: A novel omega-3
free fatty acid formulation has dramatically improved bioavailabilityduring low-fat diet compared with omega-3-acid ethyl esters: The
ECLIPSE (Epanova compared to Lovaza in a pharmacokinetic single-dose
evaluation) study. J Clin Lipidol 2012, 6(6):573–584.
32. Albert CM, Campos C, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J:
Blood Levels of long-chain n–3 fatty acids and the risk of sudden death.
N Engl J Med 2002, 346(15):1113–1118.
33. Simon JA, Hodgkins ML, Browner WS, Neuhaus JM, Bernert JT, Hulley SB:
Serum fatty acids and the risk of coronary heart disease. Am J Epidemiol
1995, 142(5):469–476.
34. Lemaitre RN, King IB, Mozaffarian D, Kuller LH, Tracy RP, Siscovick DS: N-3
Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal
myocardial infarction in older adults: the Cardiovascular Health Study.
Am J Clin Nutr 2003, 77(2):319–325.
35. Harris WS, von Schacky C: The Omega-3 Index: a new risk factor for death
from coronary heart disease? Prev Med 2004, 39(1):212–220.
36. Wallace J: Nutritional and botanical modulation of the inflammatory
cascade – eicosanoids, cyclooxygenases, and lipooxygenases – as an
adjunct in cancer therapy. Integr Cancer Ther 2002, 1(1):7–37.
37. Wall R, Ross RP, Fitzgerald GF, Stanton C: Fatty acids form fish: the anti-
inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 2010,
68(5):280–289.
38. Dessi M, Noce A, Bertucci P, Manca di Villahermosa S, Zenobi R, Castagnola
V, Addessi E, Daniele N: Atherosclerosis, dyslipidemia, and inflammation:
the significant role of polyunsaturated fatty acids. ISRN Inflamm 2013,
12:191823.
39. Cottin SC, Sanders TA, Hall WL: The differential effects of EPA and DHA on
cardiovascular risk factors. Proc Nutr Soc 2011, 70(2):215–231.
40. Serini S, Fasano E, Piccioni E, Cittadini AR, Calviello G: Differential anti-
cancer effects of purified EPA and DHA and possible mechanisms in-
volved. Curr Med Chem 2011, 18(26):4065–4075.
41. Wei MY, Jacobson TA: Effects of eicosapentaenoic acid versus
docosahexaenoic acid on serum lipids: a systematic review and meta-
analysis. Curr Atheroscler Rep 2011, 13(6):474–483.
42. Serini S, Bizzarro A, Piccioni E, Fasano E, Rossi C, Lauria A, Cittadini AR,
Masullo C, Calviello G: EPA and DHA differentially affect in vitro
inflammatory cytokine release by peripheral blood mononuclear cells
from Alzheimer’s patients. Curr Alzheimer Res 2012, 9(8):913–923.
43. Russell FD, Bürgin-Maunder CS: Distinguishing health benefits of
eicosapentaenoic and docosahexaenoic acids. Mar Drugs 2012,
10(11):2535–2559.
doi:10.1186/1476-511X-13-99
Cite this article as: Laidlaw et al.: A randomized clinical trial to determine
the efficacy of manufacturers’ recommended doses of omega-3 fatty acids
from different sources in facilitating cardiovascular disease risk reduction.
Lipids in Health and Disease 2014 13:99.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
